A new and improved algorithm for the quantification of chromatin condensation from microscopic data shows decreased chromatin condensation in regenerating axolotl limb cells by Julian Sosnik (3704914)

Temporal profiles of the key BO-NN features. by Julia Berezutskaya (9080269)

“…Right plot show the gradual decrease in the TM tuning for the features highlighted in <b>c</b> as well as the gradual increase in the temporal response profile (i.e. optimal shifts for the prediction of the key BO-NN features using Praat features shown in <b>a</b>). …”

Fig 5 - by Pierre Bauvin (18154818)

Hypoxia induced decreases in dendritic spine density, length, soma size and volume of the apical and basal branches of CA1 and CA3 pyramidal neurons. by Chun-Sing Lam (695733)

Mutation of four arginine residues in P34 leads to a decrease in binding between P34 and L5. by Anyango D. Kamina (4034165)

(a) Picture of one exposed rat with two fibromas (left)–(b) macroscopic view of the femoral tumour (right). by René de Seze (574047)

<i>Trans ε</i> viniferin decreases amyloid deposits and inflammation in a mouse transgenic Alzheimer model by Martial Caillaud (6383672)

“…Here, effects of this stilbenoid were evaluated in transgenic APPswePS1dE9 mice. We report that <i>trans ε</i>-viniferin could go through the blood brain barrier, reduces size and density of amyloid deposits and decreases reactivity of astrocytes and microglia, after a weekly intraperitoneal injection at 10 mg/kg from 3 to 6 months of age.…”

Meltrin β does not affect the expression of EphA4 on the cell surface nor the initial association between ephrin-A5 and EphA4, but decreases accessibility of antibodies that recognize the EphA4 C-terminus. by Norihiro Yumoto (270290)

Subjects:

S5 Fig - by Jordan K. Abbott (8934239)

Inhibition of G9a decreases the tumorigenicity of neuroblastoma cells. by Xiao-Xue Ke (626989)

Dosing analysis of the YFV vaccine (subcutaneous route) in interferon-1 receptor knockout mice (A129). by Ana C. Vicente Santos (11649118)

Source data for Fig 1. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 2. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 3. by Rahsan Erdem (11726357)

Subjects:

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Subjects:

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Subjects:

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Subjects:

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

Subjects:

Diarrheal disease severity by treatment group for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects: